Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase

Infection, Genetics and Evolution

Volumn 11, Issue 2, 2011, Pages 308-319

  Gupta, Shishir K ^a   Srivastava, Mugdha ^a   Akhoon, Bashir A ^b   Smita, Suchi ^c   Schmitz, Ulf ^d   Wolkenhauer, Olaf ^d   Vera, Julio ^d   Gupta, Shailendra K ^d,e  

^a Society for Biological Research and Rural Development   (India)

^b SHRI MATA VAISHNO DEVI UNIVERSITY   (India)

^c INTEGRAL UNIVERSITY   (India)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Epitope prediction; H1N1; Neuraminidase; Swine influenza

Indexed keywords

EPITOPE; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PHENYLALANYLSERYLTYROSYLLYSYLTYROSYLGLYCYLASPARAGINYLGLYCYLVALINE; POLYPEPTIDE; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ANTIGENICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONSENSUS SEQUENCE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIGENIC VARIATION; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; GENETIC DRIFT; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE;

SUIDAE; SWINE INFLUENZA VIRUS;

EID: 79951944884     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2010.10.013     Document Type: Article

References (85)

1. Akhoon B.A., Gupta S.K., Dhaliwal G., Srivastava M., Gupta S.K. Virtual screening of specific chemical compounds by exploring E. coli NAD+-dependent DNA ligase as a target for antibacterial drug discovery. J. Mol. Model. 2010, 10.1007/s00894-010-0713-9.
2. Akhoon B.A., Gupta S.K., Verma V., Dhaliwal G., Srivastava M., Gupta S.K., Ahmed R.F. In-silico designing and optimization of anti-breast cancer antibody mimetic oligopeptide targeting HER-2 in women. J. Mol. Graph. Model. 2010, 28:664-669.
3. Alexander J., Fikes J., Hoffman S., Franke E., Sacci J., Appella E., Chisari F.V., Guidotti L.G., Chesnut R.W., Livingston B., Sette A. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res. 1998, 18:79-92.
4. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. J. Mol. Biol. 1990, 215:403-410.
5. Assarsson E., Bui H.H., Sidney J., Zhang Q., Glenn J., Oseroff C., Mbawuike I.N., Alexander J., Newman M.J., Grey H., Sette A. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J. Virol. 2008, 82:12241-12251.
6. Assarsson E., Sidney J., Oseroff C., Pasquetto V., Bui H.H., Frahm N., Brander C., Peters B., Grey H., Sette A. A quantitative analysis of the variables affecting the repertoire of T-cell specificities recognized after vaccinia virus infection. J. Immunol. 2007, 178:7890-7901.
7. Azizi A., Diaz-Mitoma F. Viral peptide immunogens: current challenges and opportunities. J. Peptide Sci. 2008, 13:776-786.
8. Bernstein F.C., Koetzle T.F., Williams G.J., Meyer E.F., Brice M.D., Rodgers J.R., Kennard O., Shimanouchi T., Tasumi M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112:535-542.
9. Besselaar T.G., Botha L., McAnerney J.M., Schoub B.D. Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J. Med. Virol. 2004, 73:71-78.
10. Brusic V., August J.T. The changing field of vaccine development in the genomics era. Pharmacogenomics 2004, 5:597-600.
11. Bui H.-H., Sidney J., Dinh K., Southwood S., Newman M.J., Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics 2006, 7:153.
12. Bui H.-H., Sidney J., Li W., Fusseder N., Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 2007, 8:361.
13. Bui H.-H., Sidney J., Peters B., Sathiamurthy M., Sinichi A., Purton K.-A., Mothé B.R., Chisari F.V., Watkins D.I., Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57:304-314.
14. Camacho C.J., Katsumata Y., Ascherman D.P. Structural and thermodynamic approach to peptide immunogenicity. PLoS Comput. Biol. 2008, 4:e1000231.
15. Chaitra M.G., Hariharaputran S., Chandra N.R., Shaila M.S., Nayak R. Defining putative T-cell epitopes from PE and PPE families of proteins of Mycobacterium tuberculosis with vaccine potential. Vaccine 2005, 23:1265-1272.
16. De Groot A.S., Ardito M., McClaine E.M., Moise L., Martina W.D. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009, 27:5740-5747.
17. De Groot A.S., McMurry J., Marcon L., Franco J., Rivera D., Kutzler M., Weiner D., Martin B. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005, 23:2121-2131.
18. del Guercio M.F., Alexander J., Kubo R.T., Arrhenius T., Maewal A., Appella E., Hoffman S.L., Jones T., Valmori D., Sakaguchi K., Grey H.M., Sette A. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997, 15:441-448.
19. Doytchinova I.A., Flower D.R. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007, 8:4.
20. Doytchinova I.A., Flower D.R. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine 2007, 25:856-866.
21. Doytchinova I.A., Walshe V., Borrow P., Flower D.R. Towards the chemometric dissection of peptide - HLA-A*0201 binding affinity: comparison of local and global QSAR models. J. Comput. Aided Mol. Des. 2005, 19:203-212.
22. Drake J.W. Rates of spontaneous mutation among RNA viruses. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:4171-4175.
23. Franke E.D., Hoffman S.L., Sacci J.B., Wang R., Charoenvit Y., Appella E., Chesnut R., Alexander J., Del Guercio M.F., Sette A. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine 1999, 17:1201-1205.
24. Frankild S., de Boer R.J., Lund O., Nielsen M., Kesmir C. Amino acid similarity accounts for T-cell cross-reactivity and for " Holes" in the T-cell repertoire. PLoS One 2008, 3:e1831.
25. Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384:134-141.
26. Gavin P.J., Thomson R.B. Review of rapid diagnostic tests for influenza. Clin. Appl. Immunol. Rev. 2003, 4:151-172.
27. Ghedin E., Sengamalay N.A., Shumway M., Zaborsky J., Feldblyum T., Subbu V., Spiro D.J., Sitz J., Koo H., Bolotov P., Dernovoy D., Tatusova T., Bao Y., St George K., Taylor J., Lipman D.J., Fraser C.M., Taubenberger J.K., Salzberg S.L. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005, 437:1162-1166.
28. Gil L., Lopez C.L., Lazo I., Valdes E., Marcos R., Alonso A., Gambe J., Martin Y., Romero, Guzman M.G., Guillen G., Hermida L. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD41 and CD81 cells against viral encephalitis in mice. Int. Immunol. 2009, 21:1175-1183.
29. Girard M.P., Cherian T., Pervikov Y., Kieny M.P. A review of vaccine research and development: human acute respiratory infections. Vaccine 2005, 23:5708-5724.
30. Goh G.K.-M., Dunker A.K., Uversky V.N. Protein intrinsic disorder and influenza virulence: the 1918 H1N1and H5N1 viruses. Virology 2009, 6:69.
31. Greenbaum J.A., Kotturi M.F., Kim Y., Oseroff C., Vaughan K., Salimi N., Vita R., Ponomarenko J., Scheuermann R.H., Sette A., Peters B. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20365-20370.
32. Guan P., Doytchinova I.A., Walshe V.A., Borrow P., Flower D.R. Analysis of peptide-protein binding using amino acid descriptors: prediction and experimental verification for HLA-A*0201. J. Med. Chem. 2005, 48:7418-7425.
33. Gupta S.K., Singh A., Srivastava M., Gupta S.K., Akhoon B.A. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer. Vaccine 2009, 28:120-131.
34. Gupta S.K., Smita S., Sarangi A.N., Srivastava M., Akhoon B.A., Rahman Q., Gupta S.K. In silico CD4+ T-cell epitope prediction and HLA distribution analysis for the potential proteins of Neisseria meningitidis Serogroup B-a clue for vaccine development. Vaccine 2010, 28:7092-7097.
35. Henikoff J.G., Henikoff S. Using substitution probabilities to improve position-specific scoring matrices. Comput. Appl. Biosci. 1996, 12:135-143.
36. Huber V.C., Peltola V., Iverson A.R., McCullers J.A. Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J. Virol. 2010, 84:4105-4108.
37. Irving M.B., Pan O., Scott J.K. Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr. Opin. Chem. Biol. 2001, 5:314-324.
38. Kolaskar A.S., Tongaonkar P.C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990, 276:172-174.
39. Lanzavecchia A., Iezzi G., Viola A. From TCR engagement to T-cell activation: a kinetic view of T-cell behavior. Cell 1999, 96:1-4.
40. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J., Higgins D.G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
41. Larsen J.E., Lund O., Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006, 24:2. 10.1186/1745-7580-2-2.
42. Larsen M.V., Lundegaard C., Lamberth K., Buus S., Lund O., Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 2007, 8:424.
43. Lauemøller S.L., Kesmir C., Corbet S.L., Fomsgaard A., Holm A., Claesson M.H., Brunak S., Buus S. Identifying cytotoxic T-cell epitopes from genomic and proteomic information: " The human MHC project" Rev. Immunogenet. 2000, 2:477-491.
44. Madden D.R. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 1995, 13:587-622.
45. Maenaka K., Jones E.Y. MHC superfamily structure and the immune system. Curr. Opin. Struct. Biol. 2009, 9:745-753.
46. Marti-Renom M.A., Madhusudhan M.S., Sali A. Alignment of protein sequences by their profiles. Prot. Sci. 2004, 13:1071-1087.
47. Matrosovich M.N., Matrosovich T.Y., Gray T.N., Roberts A., Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 2004, 78:12665-12667.
48. Maupetit J., Derreumaux P., Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res. 2009, 37:498-503.
49. Maupetit J., Derreumaux P., Tuffery P. A fast and accurate method for large-scale de novo peptide structure prediction. J. Comput. Chem. 2010, 31:726-738.
50. Maurer-Stroh S., Ma J., Lee R.T.C., Sirota F.L., Eisenhaber F. Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites. Biol. Direct 2009, 4:18.
51. Nakajima K. Influenza virus genome structure and encoded proteins. Nippon Rinsho 1997, 55:2542-2546.
52. Nielsen M., Lund O., Buus S., Lundegaard C. MHC Class II epitope predictive algorithms. Immunology 2009, 130:319-328.
53. Nielsen M., Lundegaard C., Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007, 8:238.
54. Nielsen M., Lundegaard C., Worning P., Lauemøller S.L., Lamberth K., Buus S., Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Prot. Sci. 2003, 12:1007-1017.
55. Nobusawa E., Sato K. Comparison of the mutation rates of human influenza A and B viruses. J. Virol. 2006, 80:3675-3678.
56. Ovsyannikova I.G., Jacobson R.M., Poland G.A. Variation in vaccine response in normal populations. Pharmacogenomics 2004, 5:417-427.
57. Palese P., Compans R.W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J. Gen. Virol. 1976, 33:159-163.
58. Palese P., Tobita K., Ueda M., Compans R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61:397-410.
59. Parida R., Shaila M.S., Mukherjee S., Chandra N.R., Nayak R. Computational analysis of proteome of H5N1 avian infuenza virus to define T-cell epitopes with vaccine potential. Vaccine 2007, 25:7530-7539.
60. Peters B., Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005, 6:132.
61. Rabadan R., Robins H. Evolution of the influenza A virus: some new advances. Evol. Bioinform. Online 2007, 3:299-307.
62. Ross L.G., Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin. Microbiol. Rev. 2006, 19:614-636.
63. Rao X., CA Fontaine Costa A.I., van Baarle D., Kesmir C. A comparative study of HLA binding affinity and ligand diversity: implications for generating immunodominant CD8 T cell responses. J. Immunol. 2009, 182:1526-1532.
64. Reche P.A., Reinherz E.L. Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms. J. Mol. Biol. 2003, 331:623-641.
65. Rick R. Review of immunoinformatic approaches to in-silico B-cell epitope prediction. Nat. Precedings 2007, 10.1038/npre.2007.353.1.
66. Robey I.F., Edmundson A.B., Schluter S.F., Yocum D.E., Marchalonis J.J. Specificity mapping of human anti-T cell receptor monoclonal natural antibodies: defining the properties of epitope recognition promiscuity. FASEB J. 2002, 16:642-652.
67. Saito T., Taylor G., Laver W.G., Kawaoka Y., Webster R.G. Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase. J. Virol. 1994, 68:1790-1796.
68. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4:406-425.
69. Sánchez-Burgos G., Ramos-Castaneda J., Cedillo-Rivera R., Dumonteil E. Immunogenicity of novel Dengue virus epitopes identified by bioinformatic analysis. Virus Res. 2010, 53:113-120.
70. Schotsaert M., Ibanez L.I., Fiers W., Saelens X. Controlling influenza by cytotoxic T-cells: calling for help from destroyers. J. Biomed. Biotechnol. 2010, 10.1155/2010/863985.
71. Sette A., Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999, 50:201-212.
72. Shannon C.E. The mathematical theory of communication. Bell Syst. Tech. J. 1948, 27. 379-423 and 623-656.
73. Shi Y.P., Hasnain S.E., Sacci J.B., Holloway B.P., Fujioka H., Kumar N., Wohlhueter R., Hoffman S.L., Collins W.E., Lal A.A. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1615-1620.
74. Sinigaglia F., Hammer J. Motifs and supermotifs for MHC class II binding peptides. J. Exp. Med. 1995, 181:449-451.
75. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., Hoffman S., Kubo R.T., Chesnut R.W., Grey H.M., Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 1998, 160:3363-3373.
76. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368:215-221.
77. Stern L.J., Wiley D.C. Antigen peptide binding by class I and class II histocompatibility proteins. Structure 1994, 2:245-251.
78. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., Hammer J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 1999, 17:555-561.
79. Tarosso L.F., Sauer M.M., Sanabani S., Giret M.T., Tomiyama H.I., Sidney J., Piaskowski S.M., Diaz R.S., Sabino E.C., Sette A., Kalil-Filho J., Watkins D.I., Kallas E.G. Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1 infected patients who spontaneously control viral replication. PLoS One 2010, 5:e11436.
80. Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A.E., Berendsen H.J. GROMACS: fast, flexible, and free. J. Comput. Chem. 2005, 26:1701-1718.
81. Wang P., Sidney J., Dow C., Mothé B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 2008, 4:1000048.
82. Wiwanitkit V. Predicted epitopes of Lig A of Leptospira interrogans by bioinformatics method: a clue further vaccine development. Vaccine 2007, 25:2768-2770.
83. Xu X., Zhu X., Dwek R.A., Stevens J., Wilson I.A. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J. Virol. 2008, 82:10493-10501.
84. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 1999, 17:51-88.
85. Zhang Q., Wang P., Kim Y., Haste-Andersen P., Beaver J., Bourne P.E., Bui H.H., Buus S., Frankild S., Greenbaum J., Lund O., Lundegaard C., Nielsen M., Ponomarenko J., Sette A., Zhu Z., Peters B. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 2008, 36:513-518.